Kintsugi Voice is an API-first platform, we are developing novel voice biomarker infrastructure to detect signs of clinical depression and anxiety from short clips of free form speech. We help healthcare organizations scale access to mental healthcare with smarter, more accurate triage. Our technology supports multiple use-cases to help more people get the right care at the right time.  We focus on early detection that allows you to lower cost and improve patient outcomes. We have created the first clinical-grade voice biomarker diagnostic (U.S. Patent-Pending and FDA De Novo pending) to measure the severity of depression and anxiety in real-time.

• eCART is a research-based, AI-driven software as a medical device (SaMD) that utilizes a machine learning algorithm to continuously assess hospitalized patients’ risk of impending death or intensive care unit (ICU) transfer, assisting medical staff in swift and accurate recognition of patients requiring increased medical attention. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts likelihood of critical illness onset, hours before it happens.
• eCART received FDA 510(k) clearance in 2024, with clinical performance data of nearly two million hospitalizations from 21 hospitals, including an unprecedented level of real-world prospective data, to ensure consistent accuracy across geography, age, race, and top medical conditions (e.g. sepsis, COPD, heart failure). 
• Built upon more than a decade of ongoing scientific research, eCART was developed at UChicago Medicine by Dr. Dana Edelson, MD, MS and Dr. Matthew Churpek, MD, PhD and is well chronicled in published literature. The analytic and workflow have been in use in clinical practice since 2016.

At AgileMD, we are building the most advanced real-time predictive analytics and clinical pathways platform for hospitals.

To date, AgileMD tools have been used on more than 4 million patient encounters by more than 135,000 clinical users in over 250 hospitals, including some of the nation's leading academic medical centers. AgileMD's eCART clinical deterioration prediction software is FDA cleared and the first AI-powered early warning device for ward patients to go through the FDA process with real-world prospective data. 

AgileMD is backed by premier start-up partners MATTER, YCombinator, and Rock Health, and our cutting-edge analytics are built on more than decade of ongoing research at the University of Chicago. In 2021, AgileMD garnered nearly $3 million in combined federal research and development funding from the U.S. Department of Health and Human Services (HHS), including the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).

1. Kintsugi Voice only needs 20 seconds of free from speech vs. a manual screen that takes roughly 10 minutes.
2. Kintsugi Voice is language agnostic and does not listen to what a patient is saying, but how they are saying it.
3. Kintsugi has the largest annotated patient data model, validated by a psychiatrist team with more than 7 years experience. This allows us to predict depression and anxiety with high specificity and severity, based off of PHQ-9 standards.
4. Kintsugi Voice’s flexible API enables hundreds of workflows from retrospective to live in-call scoring. Typical depression screenings are typically delivered 1 time and not longitudinal. We provide the ability to longitudinally track patients across a period of time.

1. We are not a NLP tool, we do not need any canned speech and or paragraph read to detect depression and or anxiety.
2. We have the largest annotated data model in the world with over 35k patients.
3. We are supporting over 1M at risk lives.
4. 2X accuracy rating compared to the standard of care.

• Continuously monitors EHR data in real time
• Stratifies hospitalized patients by risk of impending all-cause clinical deterioration and sepsis
• Notifies inpatient providers when patient may need additional assessment and management
• Recommends clinical pathways with integrated order entry

• Authorized: FDA 510(k) cleared
• Tested: Derived and validated in nearly 3 million patient encounters across 28 hospitals
• Experienced: 8+ years in clinical use; 10+ years of published academic literature on value over other early warning scores
• Accurate: High sensitiviy and specificity, meaning fewer false alarms and more efficient focus on the highest risk patients
• Integrated: Embedded cross-team workflow ensures that risk scores are not ignored and action is taken
• Benchmarked: Robust reporting, benchmarking, and implementation support drive quality improvement